Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210917 | 0.93 | GSK3B (0.40) | ASAH1GSK3BGALR3NR2F2RAB9A | |
| SCHEMBL8218877 | 0.92 | ASAH1 (0.41) | ASAH1GSK3BPPARGKCNH2MGLL | |
| SCHEMBL8218142 | 0.91 | ASAH1 (0.45) | ASAH1GSK3BGALR3NR2F2RAB9A | |
| SCHEMBL12215826 | 0.86 | ASAH1 (0.41) | ASAH1GSK3BKCNH2MGLLHDAC1 | |
| SCHEMBL8214381 | 0.78 | ALDH1A1 (0.43) | ASAH1GSK3BKMT2AMGLLADAM17 | |
| SCHEMBL8221507 | 0.78 | ASAH1 (0.49) | ASAH1RAB9AKMT2AMGLLF12 | |
| SCHEMBL8214379 | 0.78 | ASAH1 (0.46) | ASAH1GSK3BKMT2AMGLLF12 | |
| SCHEMBL8218187 | 0.77 | ASAH1 (0.49) | ASAH1KMT2AMGLLF12KCNMA1 | |
| SCHEMBL8218911 | 0.76 | ASAH1 (0.46) | ASAH1KMT2AMGLL | |
| SCHEMBL8218185 | 0.76 | ASAH1 (0.47) | ASAH1RAB9AKMT2AMGLLADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ASAH1 31/4885GSK3B 1275/4885GALR3 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.